Reply to Gatti and Pea, "Are the pharmacokinetic data of meropenem studied in CSF of a mixed population composed of patients with cerebral infections and patients with extracerebral infections really helpful for clinicians treating CNS infections?"

Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0146824. doi: 10.1128/aac.01468-24. Epub 2024 Nov 6.
No abstract available